A short statement before this article begins, because the topic demands it: I am reporting doses from published peer-reviewed studies, not prescribing for your animal. The FDA has not approved any CBD product for use in dogs or cats. There are no official dose charts, no agency-endorsed indications, and no manufacturer warranties of efficacy. There are several well-designed clinical studies on a small number of conditions, a much larger commercial market, and a regulatory landscape that has been changing month by month for the last two years. The framework for evaluating CBD for pets follows. It distinguishes the three.
If you are weighing CBD for a specific medical condition in a specific animal, the right next step is a conversation with your veterinarian — particularly if the animal is on NSAIDs, phenobarbital, prednisone, ketoconazole, or any other liver-metabolised medication. Some US states (California, Nevada, Michigan, and as of March 2026, Maryland) explicitly protect veterinarians who discuss CBD with clients; in others, the conversation carries professional risk for the clinician. Ask anyway.
The 2025 numbers from the Dog Aging Project — a roughly 47,000-dog longitudinal cohort published in November 2025 — set the practical scale of the question: 7.3% of US companion dogs have been given CBD or hemp products, and 5.8% receive them frequently (ScienceDaily summary of Frontiers publication, Nov 2025; Frontiers in Veterinary Science press release). That is roughly one in fourteen households. The use is widespread; the institutional guidance has not caught up. This article is what I would hand a client who asks.
What the evidence actually shows — by condition
The single most useful frame for thinking about pet CBD is evidence-tier. Different conditions have very different strengths of underlying data, and the consumer marketing often flattens that. Here is the honest tier list.
Strong — canine osteoarthritis
The strongest single body of evidence in pet CBD. A 2023 Frontiers in Veterinary Science systematic review and meta-analysis of five studies found that CBD significantly reduced pain scores and increased activity in dogs with osteoarthritis (Frontiers 2023). The foundational Cornell trial (Wakshlag and colleagues, 2018, with a 2024 update) reported that more than 80% of dogs with osteoarthritis experienced a decrease in pain at the studied dose (Cornell Riney Canine Health Center). The Gamble 2018 trial corroborated the finding at a similar dose.
What this means clinically: if your dog has confirmed osteoarthritis and is on a multimodal pain management plan (with your veterinarian), CBD is the condition with the most justifiable evidence-based addition. It is not a substitute for NSAIDs, gabapentin, weight management, joint supplements, or rehabilitation — it is an adjunct.
Promising — canine epilepsy adjunct
A 39-dog double-blind randomized controlled trial out of Colorado State University (McGrath and colleagues) found fewer seizure days in dogs receiving CBD alongside their existing anticonvulsant regimen, compared to placebo (King Harvest research summary). Side effects were generally mild — vomiting, decreased appetite — and the trial was well tolerated.
What this means clinically: CBD shows promise as an adjunct to standard anticonvulsant therapy in dogs with idiopathic epilepsy. The clinical decision to add CBD belongs with your veterinary neurologist, particularly because of the CYP450 interaction with phenobarbital (covered below).
Mixed — canine anxiety
This is the condition where consumer expectation and clinical evidence diverge most sharply, and the picture has shifted in 2025.
Cornell's own anxiety study reported that 83% of dogs given CBD chews before a stressful event showed a decrease in stress- or anxiety-related behaviors — positive. But the November 2025 Dog Aging Project analysis of long-term CBD use across roughly 47,000 dogs found a more textured result: dogs on long-term CBD were initially more aggressive than non-users but became less aggressive over time, while other anxious behaviours did not improve (Frontiers/ScienceDaily, Nov 2025). A 2023 RCT (Hunt and colleagues) on situational anxiety produced a similarly mixed signal.
What this means clinically: CBD may help acute, situational anxiety (thunderstorms, fireworks, vet visits) and may produce a slow modulation of aggression over months, but should not be expected to resolve generalized anxiety the way standard veterinary-behavior pharmacology (fluoxetine, trazodone, clomipramine) can. Behavior modification + a credentialed veterinary behaviorist remains the foundation.
Weak — cancer, generalized wellness, dermatitis
A single positive trial in atopic dermatitis (CannPal canine atopic dermatitis study, where 65% of treated dogs showed at least 50% reduction in itching/chewing and half recovered completely, per Cornell's summary) is interesting but not yet replicated. Cancer claims circulate widely in consumer marketing and have no comparable clinical evidence base in dogs or cats. Generalized "wellness" claims are pre-clinical extrapolation.
What this means clinically: I would not start CBD for any of these indications outside a clinical trial or a specific recommendation from your veterinarian. The FDA's April 2025 warning letters to four pet CBD makers (CBD Dog Health, MycoDog, Bailey's CBD, HolistaPet) specifically cite disease-treatment claims — including cancer claims — as illegal animal-drug marketing (Vicente LLP analysis of FDA warning letters).
A dosing reference — from the published studies
A reminder before this section: what follows is what the peer-reviewed studies have used. It is not a prescription. Talk to your veterinarian before initiating CBD, especially if your animal is on any of the drugs listed in the next section.
Doses are reported from the studies as CBD mg per kg of body weight, given orally.
| Condition | Published dose (per study) | Frequency | Source |
|---|---|---|---|
| Canine osteoarthritis | 2 mg/kg | Twice daily (BID) | Wakshlag et al. 2018; Gamble et al. 2018 |
| Canine epilepsy adjunct | 2.5 mg/kg titrating to 5 mg/kg | Twice daily (BID) | McGrath et al. 2019 (CSU 39-dog RCT) |
| Canine antipruritic (4.5 mg/kg study) | 4.5 mg/kg | Once daily (SID) | Frontiers 2023 update review of healthy-dog antipruritic study |
| Acute situational anxiety (CBD chew) | Product-specific (manufacturer dose) | 1–2 hours before stressor | Cornell anxiety chew data |
A practical body-weight conversion to per-dog mg is the next step most owners want; that conversion is straightforward:
| Dog weight | OA dose at 2 mg/kg (per dose, BID) | Epilepsy dose at 2.5 mg/kg (per dose, BID) |
|---|---|---|
| 10 kg (~22 lb) | 20 mg | 25 mg |
| 20 kg (~44 lb) | 40 mg | 50 mg |
| 30 kg (~66 lb) | 60 mg | 75 mg |
| 40 kg (~88 lb) | 80 mg | 100 mg |
| 50 kg (~110 lb) | 100 mg | 125 mg |
Dosing principles, regardless of condition:
- Start low and titrate slowly. Most veterinary clinicians experienced with CBD start at half the target study dose for the first 7–14 days and titrate up as tolerated.
- Time the dose to the activity that matters. For OA, twice-daily steady-state matters; for situational anxiety, dose 1–2 hours before the stressor.
- Measure response with something objective. For OA, the Canine Brief Pain Inventory or the AAHA pain assessment. For epilepsy, seizure diary frequency. For anxiety, a behavior log with named triggers. "She seems calmer" is not evidence.
- Monitor liver enzymes. Baseline alkaline phosphatase (ALP) before starting and at 6 weeks; persistent elevation is a known finding in dogs on CBD and warrants a conversation with your vet.
CBD for cats — the section every other consumer page leaves out
This section exists because the cat-CBD search demand is large (roughly 7,200 searches a month combined on cbd for cats and cbd oil for cats) and the consumer SERP has effectively no institutional coverage of feline pharmacokinetics. The data here are smaller than for dogs but informative.
Feline pharmacokinetics — why cats are not small dogs in CBD dosing:
- Half-life is shorter at the doses studied: roughly 1.5–2.1 hours at 2 mg/kg in single-dose escalation studies (PMC10092881). Steady-state PK with a CBD/CBDA hemp paste showed a similar pattern over 24-hour and 1-week dosing (PMC9355628).
- Cats have limited hepatic glucuronidation capacity. This is the same physiological reason cats are more sensitive to acetaminophen and to many essential-oil phenols, and it matters here because glucuronidation is one of the routes by which CBD and its metabolites are cleared. The practical implication is lower starting doses and slower titration than would be appropriate in a dog of similar weight.
- Acute single-dose tolerance is broad. Single doses up to 80 mg/kg of CBD oil were well tolerated in cats in escalation studies — an acute tolerance ceiling, not a chronic dosing recommendation.
- 12-week tolerability in healthy cats showed no physical-exam changes and few CBC/chemistry changes, with one cat developing persistent ALT elevation (Frontiers 2023 — Healthy cats tolerate long-term daily feeding of cannabidiol). Liver enzyme monitoring at baseline and at 6 weeks is sensible.
Practical cat-CBD framework, with the same do-not-prescribe gate:
- Starting doses in the cat literature run substantially lower than dog OA doses — roughly 0.1–0.5 mg/kg as a starting point, titrated slowly. Specific products vary in absorption; the manufacturer's mg/mL potency disclosure and a third-party COA are essential.
- Twice-daily dosing matches the half-life data better than once-daily for sustained levels, though the choice depends on the indication.
- Avoid products containing xylitol or measurable THC. Both are toxic to cats; xylitol catastrophically so, even in small amounts.
- Liver enzymes (ALT) at baseline and at 6 weeks for any cat on a chronic regimen.
- Stop and consult your veterinarian at the first sign of vomiting, persistent lethargy, anorexia, or ataxia.
What I will not tell you here is what to feed your specific cat. That conversation depends on her age, weight, current medications, and the specific condition you're trying to address — and that conversation belongs in your veterinarian's exam room, ideally in a state where the law explicitly permits it.
CBD and your pet's other medications — the CYP450 interaction
This is the section the consumer SERP routinely under-develops, and it is the single most clinically important safety fact in the article.
The mechanism: CBD inhibits the cytochrome P450 (CYP450) family of liver enzymes — specifically CYP2C and CYP3A in dogs — which are the primary enzymes responsible for metabolizing a large fraction of veterinary drugs. The clinical consequence is that drugs co-administered with CBD may be cleared more slowly than expected, producing higher and longer-lasting drug levels at the same dose.
The drug classes most clinically important to flag:
- NSAIDs — carprofen (Rimadyl), meloxicam (Metacam), deracoxib (Deramaxx), grapiprant (Galliprant). CBD plus NSAID combinations may amplify hepatic and renal stress; baseline and follow-up bloodwork are sensible.
- Anticonvulsants — phenobarbital, levetiracetam (Keppra), zonisamide. This is the most clinically relevant interaction because the dogs most likely to be on CBD for seizures are also on phenobarbital, and the level monitoring matters.
- Corticosteroids — prednisone, prednisolone. CBD + steroid combinations can amplify immunosuppression at the same dose.
- Antifungals — ketoconazole, itraconazole. Pre-existing CYP-inhibitor profile compounded by CBD.
- Heart medications and sedatives in some dogs.
The other consistent laboratory finding in dogs on CBD is alkaline phosphatase (ALP) elevation — well-documented across multiple studies, generally reversible on discontinuation, but warranting baseline and follow-up bloodwork. The Frontiers 2023 update review of CBD pharmacokinetics, efficacy, and safety in dogs documents this as the most consistent CBD-related laboratory abnormality (Frontiers 2023 update review).
The clinical bottom line: never start CBD in a pet who is on any of the drug classes above without discussing the plan with your veterinarian first. The interaction is not theoretical, and the drug-level consequences are real.
Related Article: The Rise of Exotic Pets: Care Tips for Unconventional Companions
The 2024–2026 regulatory landscape
The legal and enforcement picture has changed materially in the last 24 months — most consumer articles have not been updated to reflect it. A timeline:
- 2018 — Farm Bill. Federally legalizes hemp and hemp-derived CBD (≤0.3% THC). Does not authorize CBD as a drug, dietary supplement, or food additive at the federal level.
- 2022 — AVMA House of Delegates policy. The American Veterinary Medical Association formally adopts policy on cannabis in veterinary medicine, supporting continued research and clarifying that the AVMA does not endorse use without further investigation.
- August 2025 — AAFCO approval of hempseed meal as a feed ingredient for laying hens. First AAFCO Official Publication entry for a hemp-derived feed ingredient (up to 20% inclusion). Cannabinoid-rich plant fractions, stalks, and flowers remain excluded. This is not a CBD endorsement for pet food; the conflation is common and worth correcting (Cannabis Business Times, Aug 2025). The Hemp Feed Coalition's next application targets ruminants; pet feed remains outside the framework.
- January 16, 2025 — FDA Federal Register Request for Information on cannabis-derived products in veterinary practice (Docket FDA-2025-N-0001). The first formal FDA-CVM step toward a veterinary cannabinoid policy framework. Comments were open through Spring 2025 (Federal Register). The signal: the regulatory grey zone is starting to close, but no FDA-approved or indexed animal drugs containing CBD existed as of 2026.
- April 2025 — FDA issues warning letters to four pet-CBD makers: CBD Dog Health, MycoDog, Bailey's CBD, and HolistaPet, citing disease-treatment claims on websites and social channels as unapproved-animal-drug marketing (FDA Cannabis-Derived Products warning letters; Vicente LLP analysis).
- March 2026 — Maryland HB 1006 (passed), protecting veterinarians from licensing-board discipline for discussing cannabis treatment options with pet owners. Maryland joins California (AB-1885), Nevada, and Michigan in the small US club of states where veterinarians can legally discuss CBD with clients without sanction (CBD World News, April 2026).
The category itself has continued to grow despite the regulatory ambiguity: the pet-CBD market is projected at roughly $600 million in 2026, with industry analysts modeling 33% compound annual growth through the next decade. The mismatch between commercial scale and regulatory framework is the dominant fact about the category in 2026.
Brand vetting — the 5 questions to ask any pet CBD seller
A Wakshlag-cited product audit of 29 commercial pet-CBD products found that only 10 matched their label cannabinoid claims within 10%, 2 contained no cannabinoids at all, and 4 had heavy-metal contamination (Cornell Riney Canine Health Center summary). That is roughly one-third of products in compliance with what they say on the bottle. Brand vetting is not optional in this category.
Five questions to ask any pet CBD seller. The willingness to answer is itself a signal.
- Will you provide a current third-party Certificate of Analysis (COA) for the batch I'm buying, showing cannabinoid potency and contaminant testing? The COA should be batch-specific, recent, and from an independent ISO-accredited lab. "Lab tested" without the document is marketing, not evidence.
- Do you carry the NASC quality seal? The National Animal Supplement Council audits manufacturer quality processes and is the closest thing to a voluntary industry standard. Not a regulatory approval, but a real screening criterion.
- Is the CBD potency stated in mg per mL of oil, with a recommended dose per kg of body weight? "Strong" and "mild" are not units of measurement. mg/mL is.
- Where is the hemp grown, and is it US-grown organic? Hemp is a phytoremediation crop — it accumulates heavy metals and contaminants from the soil. Source matters.
- Does the product label avoid structure-function claims like "treats arthritis" or "cures anxiety"? The FDA's April 2025 warning letters specifically cite those phrases as illegal animal-drug claims. A brand willing to make them is a brand whose regulatory hygiene is a problem.
What I will not do in this article is recommend specific brands. The category churns; the audit results vary product to product; and a brand recommendation in 2026 may be wrong by 2027. The five questions above are durable.
CBD for senior dogs — a brief note
A practical observation from the Dog Aging Project 2025 data: CBD use is concentrated in older, ailing dogs — animals with arthritis, cognitive decline, and end-of-life cancer care. The 7.3% and 5.8% figures cited at the top of this piece are population-level; the per-disease-cohort figures are substantially higher.
For senior dogs specifically:
- The OA evidence tier is the strongest indication. A senior dog on a multimodal OA protocol (NSAID + weight management + joint support + rehabilitation) where pain is incompletely controlled is the textbook candidate for adding CBD under veterinary supervision.
- Liver enzyme monitoring is more important, not less, because senior dogs often have age-related hepatic changes already.
- Drug-interaction profiles compound because senior dogs are often on more medications. Re-check the CYP450 list above carefully.
- End-of-life palliative use is a conversation many veterinarians are willing to have with the families they work with, particularly in states where the law explicitly permits it.
When to call your veterinarian
The decision rules I would give a client at the end of an exam-room conversation:
- Before starting any CBD regimen — and especially if your pet is on NSAIDs, phenobarbital, prednisone, ketoconazole, or any liver-metabolised medication. The CYP450 interactions are real.
- Before starting CBD in a senior pet, a pet with known liver disease, or a pet on multiple medications. Baseline liver enzymes and a medication review.
- If your pet develops vomiting, lethargy, ataxia, or anorexia after starting CBD. Same-day call; the conversation will be either "discontinue and observe" or "come in for bloodwork."
- If you are considering CBD for cancer, generalized anxiety, or any condition outside the strong-evidence tier above. The evidence-based options for those conditions are usually different and better-supported.
- If you live in a state where veterinarians cannot legally discuss CBD, and you still want to start a regimen. Ask the question anyway. The clinician's response will tell you whether your state is in the protected club; if not, ask whether there's a referral path to a veterinary specialist (often a veterinary internist, behaviorist, or neurologist) who can have the conversation.
The honest 2026 summary on CBD for pets: the strongest single use case is canine osteoarthritis adjunct therapy; the second is canine epilepsy adjunct; the rest of the categories are weaker than the marketing suggests; the product quality is variable enough that brand vetting matters more than dose precision; and the regulatory landscape is shifting in a direction that will likely produce clearer FDA-approved or indexed animal drugs containing CBD within the next several years. None of that changes the rule at the top of this article. The dose belongs to the study; the prescription belongs to your veterinarian.
Frequently Asked Questions
Most peer-reviewed canine CBD studies use 2 mg/kg of body weight twice daily for osteoarthritis (Wakshlag 2018, Gamble 2018) and titrate up to 2.5–5 mg/kg twice daily for epilepsy adjunctive use (McGrath CSU 2019). The FDA has not approved any animal CBD product, so there is no official dosing chart. Start at the low end of the study range, monitor for sedation or GI upset, and consult your veterinarian first — especially if your dog is on NSAIDs, phenobarbital, prednisone, ketoconazole, or other liver-metabolised drugs.
Short-term feline studies suggest yes — single doses up to 80 mg/kg were tolerated, and a 12-week daily-feeding study in healthy cats showed minimal CBC/chemistry changes (one cat developed persistent ALT elevation). But cats have limited hepatic glucuronidation and clear CBD differently than dogs, with a half-life around 1.5–2.1 hours at 2 mg/kg. Start much lower than dog doses (0.1–0.5 mg/kg), monitor liver enzymes (ALT) at baseline and 6 weeks, and avoid any product containing xylitol or measurable THC.
Hemp-derived CBD with no more than 0.3% THC is federally legal under the 2018 Farm Bill, but the FDA has not approved any CBD product for animal use and continues to issue warning letters to pet-CBD sellers making disease-treatment claims (most recently April 2025 to CBD Dog Health, MycoDog, Bailey's CBD, and HolistaPet). California (AB-1885), Nevada, Michigan, and as of March 2026 Maryland (HB 1006) explicitly protect veterinarians who discuss CBD with clients; in other states, the conversation carries professional risk for the clinician.
The most commonly documented effects are sedation, GI upset (nausea, vomiting, diarrhoea), and a consistent elevation in alkaline phosphatase (ALP) liver enzyme. CBD also inhibits cytochrome P450 enzymes, which can slow the metabolism of NSAIDs (carprofen, meloxicam), anticonvulsants (phenobarbital, levetiracetam), corticosteroids (prednisone), and antifungals (ketoconazole) — producing higher and longer-lasting drug levels than the dose alone would suggest. Baseline plus 6-week liver-enzyme monitoring is sensible if your dog stays on CBD long-term.
Ask for: (1) a current batch-specific third-party Certificate of Analysis (COA) showing cannabinoid potency and contaminant testing; (2) the NASC quality seal; (3) mg/mL CBD potency clearly stated on the label with a per-kg dose recommendation; (4) US-grown organic hemp sourcing; (5) labels that avoid structure-function claims like 'treats arthritis' (the FDA treats those as illegal animal-drug claims). A Wakshlag-cited audit of 29 pet CBD products found only 10 matched their label cannabinoid claims, 2 contained no cannabinoids at all, and 4 had heavy-metal contamination.
The strongest peer-reviewed evidence is in canine osteoarthritis (Frontiers 2023 meta-analysis of five studies, plus the Cornell/Wakshlag trial showing >80% of treated dogs experienced a decrease in pain). Canine epilepsy adjunct therapy is promising based on the McGrath/CSU 39-dog double-blind RCT. Anxiety evidence is mixed — Cornell's chew study was positive (83%) but the November 2025 Dog Aging Project analysis (~47,000 dogs) found long-term CBD dogs were initially more aggressive than non-users and only slowly became less aggressive, with other anxious behaviours unchanged. Cancer and generalized-wellness claims have weak evidence and are the focus of the FDA's April 2025 enforcement actions.
